Nimodipino Altan (Nimodipine)

Nimodipine is used in the management of cerebrovascular complications, primarily targeting the cascade that leads to cerebral vasospasm after subarachnoid hemorrhage.

• Cerebral vasospasm after subarachnoid hemorrhage: reduces the incidence of delayed ischemic neurological deficits.
• Aneurysmal subarachnoid hemorrhage: improves cerebral blood flow during the acute phase.
• Secondary brain injury following SAH: provides neuroprotective effects by stabilizing neuronal calcium homeostasis.

• Nimodipine selectively antagonizes L‑type calcium channels on vascular smooth‑muscle and neuronal cells, decreasing calcium influx. This action relaxes cerebral arterial smooth muscle, producing vasodilation of intracranial vessels, and limits calcium‑mediated excitotoxic injury in neurons, thereby improving cerebral perfusion and offering neuroprotection after subarachnoid hemorrhage. The drug’s high lipophilicity allows rapid crossing of the blood‑brain barrier, achieving therapeutic concentrations in the cerebrospinal fluid. By maintaining arterial diameter, it mitigates the risk of ischemia during the critical days following hemorrhage.

Nimodipine may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Headache: mild to moderate intensity.
• Hypotension: transient drop in blood pressure.
• Nausea: occasional gastrointestinal upset.
• Flushing: warm sensation and reddening of skin.
• Dizziness: sensation of light‑headedness.
• Peripheral edema: mild swelling of extremities.

Serious or Rare Side Effects

• Severe hypotension: may require medical intervention.
• Myocardial infarction: rare but reported in vulnerable patients.
• Hepatic dysfunction: elevated liver enzymes.
• Allergic reactions: rash, pruritus, or anaphylaxis.
• Seizures: extremely rare neurological event.

Before initiating therapy, clinicians should consider several safety measures.

• Blood pressure monitoring: check systolic and diastolic values before and during therapy.
• Hepatic function assessment: evaluate liver enzymes prior to initiation.
• Concomitant vasodilators: avoid or use with caution due to additive hypotensive effect.
• Cardiac conduction disorders: monitor ECG in patients with known arrhythmias.
• Pregnancy and lactation: use only if benefit outweighs risk after specialist consultation.
• Store at ambient temperature: keep in original container, protect from moisture and light.

Nimodipine can interact with other medicines, requiring attention to the level of risk.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations.
• Other potent vasodilators (e.g., nitroglycerin): additive hypotensive effect.
• Concurrent calcium‑channel blockers: risk of severe hypotension.

Moderate Interactions (Monitor Closely)

• Antihypertensive agents (e.g., ACE inhibitors, ARBs): may enhance blood‑pressure lowering.
• Beta‑blockers: combined effect on heart rate and blood pressure.
• Diuretics: potential electrolyte disturbances.
• Antiplatelet or anticoagulant therapy: monitor for bleeding risk.